Anthony J. Rothschild, MD, says that barriers to expensive antipsychotic drugs are shortsighted. He adds that the American Psychiatric Association, in accordance with some in Congress, recently rejected a CMS decision that would have restricted the number of antidepressants and antipsychotics Medicare beneficiaries could receive.
Anthony J. Rothschild, MD, says that barriers to expensive antipsychotic drugs are shortsighted. He adds that the American Psychiatric Association, in accordance with some in Congress, recently rejected a CMS decision that would have restricted the number of antidepressants and antipsychotics Medicare beneficiaries could receive.
Dr Rothschild is professor and Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School; director, UMass Medical Depression Center and Center for Psychopharmacologic Research and Treatment, and program director, Mood Disorders Comprehensive Consultation Clinic at UMass Memorial Medical Center.
“The bottom line is—whether it’s the state’s Medicaid or the federal government on Medicare—is that the amount of money you save on the price of the pill is small compared to the amount of money you might save by giving effective medications, because people are using less healthcare services, both mental and physical,” says Dr Rothschild.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More